Characteristics of Menopause: What Impact on Risk of CHD?

January 16th 2025

USPSTF Issues Final Recommendations on Osteoporosis Screening to Prevent Fractures

The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.

Elinzanetant VMS update: As Positive Results Pile Up, Bayer Readies for Menopause Treatment’s Future

The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.

Patient Care Staff

Atumelnant Demonstrates Rapid and Sustained Biomarker Reduction in Phase 2 Trial in Adults with Congenital Adrenal Hyperplasia

FDA action date set for July 26, 2025.

January 10th 2025

Elinzanetant Meets All Endpoints in Phase 3 Study of VMS Caused by Adjuvant Endocrine Therapy for Breast Cancer

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

January 9th 2025

Prenatal Antibiotic Exposure Linked to Childhood Health Issues: Daily Dose

Elinzanetant produced a statistically significant reduction in frequency of treatment-related vasomotor symptoms as early as week 1 and in severity at weeks 4 and 12.

January 7th 2025

Machine Learning Identifies Risk Factors for Severe Cognitive Decline During Menopause

Your daily dose of the clinical news you may have missed.

Related Content

January 16th 2025

USPSTF Issues Final Recommendations on Osteoporosis Screening to Prevent Fractures

The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.

Elinzanetant VMS update: As Positive Results Pile Up, Bayer Readies for Menopause Treatment’s Future

The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.

Patient Care Staff

Atumelnant Demonstrates Rapid and Sustained Biomarker Reduction in Phase 2 Trial in Adults with Congenital Adrenal Hyperplasia

FDA action date set for July 26, 2025.

January 10th 2025

Elinzanetant Meets All Endpoints in Phase 3 Study of VMS Caused by Adjuvant Endocrine Therapy for Breast Cancer

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

January 9th 2025

Prenatal Antibiotic Exposure Linked to Childhood Health Issues: Daily Dose

Elinzanetant produced a statistically significant reduction in frequency of treatment-related vasomotor symptoms as early as week 1 and in severity at weeks 4 and 12.

January 7th 2025